Herpes Zoster (HZ)
Conditions
Interventions
Test group:Transcutaneous auricular vagus nerve stimulation
Control group:The control group received sham stimulation as a control.
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clear diagnosis: patients must meet the internationally recognized diagnostic criteria, herpes zoster blister crusting stage or rash after healing and accompanied by obvious nerve pain abnormalities. 2. Age and gender: not limited by age and gender. 3. Pain degree: visual analogue scale (VAS) was used to evaluate the pain, and VAS score >=3 points. 4. Informed consent: patients must fully understand the content of the study and voluntarily sign an informed consent form to accept transcutaneous auricular vagus nerve stimulation (taVNS) treatment and related testing and evaluation.
Exclusion criteria
Exclusion criteria: 1.Exclusion criteria encompass comorbid systemic disorders including but not limited to: Active malignancies (histologically confirmed within 5 years) Decompensated cardiovascular/cerebrovascular disorders (NYHA Class III-IV heart failure or mRS >=3) Hepatic/renal insufficiency (Child-Pugh B-C or eGFR =15 or GAD-7 >=15) Poorly controlled diabetes mellitus (HbA1c >7.5%)These comorbidities may confound taVNS therapeutic outcomes or potentiate intervention-related risks; 2.Contraindications for tVNS: Patients with sinus bradycardia (<50 bpm at rest) or sick sinus syndrome (SSS) Individuals diagnosed with ventricular arrhythmias, Subjects with implanted cardiac pacemakers/defibrillators or undergoing concurrent electrical stimulation therapies; 3.Concurrent clinical trial participation: Active enrollment in any interventional study Participation in other clinical trials within the preceding 12 weeks (verified via ClinicalTrials.gov cross-check); 4.Non-adherence to protocol requirements: Documented inability to cooperate with taVNS procedures, Poor compliance (<80% treatment session attendance) validated by Medication Adherence Report Scale (MARS); 5.Confounding variables: Concurrent enrollment in observational/therapeutic studies (excluding registry studies) Any concomitant interventions potentially affecting autonomic nervous system function;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life (assessed using the SF-36), McGill Pain Questionnaire;Serotonin [5-HT], Norepinephrine [NE], Acetylcholine [ACh], Dopamine [DA], Interleukin-1 [IL-1], Interleukin-6 [IL-6], Interleukin-10 [IL-10], Tumor Necrosis Factor-alpha [TNF-a]; | — |
Countries
China
Contacts
Public ContactTang Jing
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed